AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SAN DIEGO, Nov. 27, 2017 -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that its Chief Executive Officer, Ms. Reggie Groves, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 2:10 p.m. US EST. The conference is being held at the Lotte New York Palace in New York City.
The presentation materials to be delivered at the conference are available in the Investor Relations section of REVA’s website at www.revamedical.com.
About REVA Medical
REVA Medical is a medical device company focused on the development and commercialization of bioresorobable polymer technologies for vascular applications. The Company’s lead product, the Fantom bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the United States and Europe.
| United States | Australia | Australia |
| Investor & Media Enquiries: | Investor Enquiries: | Media Enquiries: |
| REVA Medical, Inc. | Inteq Limited | Buchan Consulting |
| Brandi Roberts | Kim Jacobs | Rebecca Wilson |
| Chief Financial Officer | +61 438 217 279 | +61 3 9866 4722 |
| +1 858-966-3003 | Andrew Cohen | |
| Cheryl Liberatore | +61 408 333 452 | |
| Director, Communications | ||
| +1 858-966-3045 | ||
| [email protected] |
